Back to Search
Start Over
Cognitive Outcomes in Nonacute Patients With Schizophrenia Treated With Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics.
- Source :
-
American journal of therapeutics [Am J Ther] 2024 May-Jun 01; Vol. 31 (3), pp. e219-e228. - Publication Year :
- 2024
-
Abstract
- Background: Patients with schizophrenia often face challenges related to cognitive function, affecting their daily functioning and overall quality of life. The choice of antipsychotic treatment may play a crucial role in determining cognitive outcomes.<br />Study Question: Our study aimed to investigate whether there was a difference in cognitive ability between the patients with schizophrenia receiving oral antipsychotics (OAP) versus long-acting injectable antipsychotics (LAI-APs).<br />Study Design: We conducted a cross-sectional study using analytical methods between January 1, 2020, and January 1, 2022. Participants were divided into 2 groups: patients undergoing treatment with OAP and patients undergoing treatment with LAI-AP. All participants underwent version A of Brief Assessment of Cognition in Schizophrenia (BACS).<br />Measures and Outcomes: The primary objective was to compare cognitive function in patients with schizophrenia treated with LAI antipsychotics versus OAP using BACS. Primary outcome measures include overall BACS score, with secondary measures focusing on specific cognitive domains. This study contributes to the understanding of the cognitive effects of different antipsychotic formulations in schizophrenia treatment.<br />Results: Although there was a slightly higher intelligence quotient in the LAI-AP group (102.2 vs. 101.32, P = 0.5401), it was not statistically significant. Olanzapine was the most commonly prescribed antipsychotic, with 48% of patients in the LAI-AP group and 40% in the OAP group. The LAI-AP group outperformed in all BACS evaluations. The most notable difference was in the token motor task (57.78 ± 17.03 vs. 50.04 ± 18.82, P = 0.0335), while the Tower of London test showed the smallest difference (17.26 ± 2.61 vs. 15.48 ± 3.47, P = 0.0046). Regression analysis revealed no significant variance in intelligence quotient scores; however, a significant discrepancy in BACS scores was evident, favoring the LAI treatment for better cognitive outcomes.<br />Conclusions: The use of long-acting antipsychotic treatment in individuals with schizophrenia offers promising advantages in preserving cognitive function.<br />Competing Interests: The authors have no conflicts of interest to declare.<br /> (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Subjects :
- Humans
Male
Female
Cross-Sectional Studies
Adult
Administration, Oral
Middle Aged
Injections
Schizophrenic Psychology
Quality of Life
Olanzapine administration & dosage
Olanzapine therapeutic use
Antipsychotic Agents administration & dosage
Antipsychotic Agents therapeutic use
Schizophrenia drug therapy
Delayed-Action Preparations
Cognition drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1536-3686
- Volume :
- 31
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- American journal of therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 38691662
- Full Text :
- https://doi.org/10.1097/MJT.0000000000001729